Citigroup cuts Ultragenyx Pharma price target to $28.00
Citigroup cut its price target for Ultragenyx Pharma to $28.00 per share from $58.00, while maintaining a Buy rating,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.